Summary："Breakthrough Treatment for Chronic Hives: Rhapsody Offers New Hope for Patients"Basel, June 12, 202

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

"Breakthrough Treatment for Chronic Hives: Rhapsody Offers New Hope for Patients"

Basel, June 12, 2026 – In a significant advancement in the treatment of chronic inducible urticaria (CIndU), Novartis has unveiled promising results from the RemIND trial, presented today at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. The data showcases that Rhapsido® (remibrutinib), a highly selective Bruton's tyrosine kinase (BTK) inhibitor, successfully met its primary endpoints across the three most common forms of CIndU.

The RemIND trial's positive outcome marks a crucial milestone in addressing the unmet medical needs of patients suffering from chronic hives, a condition characterized by recurring episodes of itchy hives. For many, CIndU significantly impacts quality of life, causing discomfort, disfigurement, and emotional distress. Current treatments often fall short in providing adequate relief, underscoring the urgent need for innovative therapies.

Industry analysts are hailing Rhapsido as a potential game-changer in the management of CIndU. With its novel mechanism of action targeting BTK, Rhapsido has demonstrated not only efficacy but also a favorable safety profile. This breakthrough is poised to redefine treatment paradigms, offering patients a much-needed alternative to existing options. The success of Rhapsido could also spur further research into BTK inhibitors for other allergic and autoimmune conditions, potentially unlocking new therapeutic avenues.

As Rhapsido moves forward in the regulatory process, the outlook for patients with CIndU is becoming increasingly optimistic. Novartis's commitment to advancing Rhapsido underscores the company's dedication to addressing complex medical challenges. With its innovative approach and the backing of robust clinical data, Rhapsido is well-positioned to make a meaningful difference in the lives of those affected by chronic hives.

In conclusion, the positive results from the RemIND trial represent a significant breakthrough in the treatment of CIndU. As the medical community continues to embrace innovative solutions, Rhapsido stands out as a beacon of hope for patients seeking effective relief from chronic hives. With its potential to transform treatment landscapes, Rhapsido is set to leave a lasting impact on the field of allergy and immunology.